Gloucester Pharmaceuticals Announces Presentation Of Romidepsin Data At 2007 American Society Of Hematology (ASH) Annual Meeting

Main Category: Cancer / Oncology
Also Included In: Pharma Industry / Biotech Industry;  Clinical Trials / Drug Trials;  Blood / Hematology
Article Date: 03 Dec 2007 - 3:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced that two abstracts detailing results from clinical trials of the Company's lead product candidate, romidepsin, will be presented at the 2007 American Society of Hematology's 49th Annual Meeting, to be held December 8-11 in Atlanta, Georgia.

Dr. Miles Prince, Chair of Clinical Cancer Services at the Peter MacCallum Cancer Centre, will present Abstract #1167 "Safety and Efficacy of the Combination of Bortezomib with the Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed and Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial" in a poster session on Saturday, December 8, 2007.

Dr. Youn H. Kim, of the Stanford Comprehensive Cancer Center, will present Abstract #123 "Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study" in an oral session on Sunday, December 9, 2007.

Copies of these abstracts are now available and can be viewed on-line through the ASH website: http://www.hematology.org.

About Romidepsin

Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which includes CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan Drug status for the treatment of both CTCL and PTCL. Fast Track status for CTCL and PTCL has also been designated by the FDA. Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately-held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA.

Gloucester Pharmaceuticals, Inc.